Chia‐Chi Lin

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Kei Muro, Hyun Cheol Chung, Veena Shankaran et al. · The Lancet Oncology · 2016 · 1.1K citations · Full text

Gastrointestinal Oncology, Medicine, Pathology +5

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta et al. · Journal of Clinical Oncology · 2016 · 846 citations · Full text

Antitumor Activity, Immunology, Pathology +16

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Benjamin Solomon, Benjamin Besse, Todd M. Bauer et al. · The Lancet Oncology · 2018 · 772 citations

Oncology, Pathology, Bronchial Neoplasm +6

Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

James Chih‐Hsin Yang, Myung‐Ju Ahn, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2017 · 563 citations · Full text

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

Alexander Drilon, Salvatore Siena, Rafał Dziadziuszko et al. · The Lancet Oncology · 2019 · 516 citations · Full text